Linda T. Vahdat, MD, MBA, is a Professor of Medicine at Weill Cornell Medical College as well as an Attending Physician at NewYork-Presbyterian Hospital in New York City. She is currently the Director of the Breast Cancer Research Program, at Weill Cornell Medicine and Co-Leader of the Breast Cancer Program within the Meyer Cancer Center. Until recently, she led the Solid Tumor Service at Weill Cornell, stepping down in 2015 to focus more on breast cancer-related activities.
Dr. Vahdat earned her undergraduate degree at Barnard College/Columbia University in New York City and completed her medical degree at Mount Sinai School of Medicine. She remained at Mount Sinai for her residency training in Internal Medicine and completed fellowship training in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center (MSKCC). In 2014, Dr. Vahdat completed a master’s degree in business administration (MBA) at the Sloan School of Management at the Massachusetts Institute of Technology. She found it to be a perfect complement to her research activities since the program focused on management, operations, entrepreneurship and data analytics.
Although a translational breast cancer medical oncologist by training, Dr. Vahdat’s expertise is in drug development. She has been involved in the identification, conceptualization, design and execution of Phase 0 through III clinical trials of new therapies in high-risk adjuvant and metastatic breast cancer patients since 1994. She has led two separate drug development efforts that led to the FDA approval of two leading drugs to fight metastatic breast cancer, and her team has taken the lead for at least two other drugs that have a high probability of success, both in triple negative breast cancer. In 2014, she founded the Triple Negative Breast Cancer Clinic -- one of only two dedicated clinics in the U.S. Dr. Vahdat’s other significant research interests include preventing breast cancer metastases and minimizing side effects of treatment, including chemotherapy-induced peripheral neuropathy. She is motivated to integrate new technology into translational medicine and has a number of collaborations both at Cornell Biogengineering and at MIT that she hopes will change how we view and treat cancer. She has also been actively involved and has held several leadership positions in the American Society of Clinical Oncology (ASCO), including Co-Chair of ASCO Breast Cancer Symposium. Dr. Vahdat also served on the Executive Board of Cancer Care from 2006 until 2012.
Please contact the doctor's office to verify that your insurance is accepted.
Aetna [HMO, Medicare, PPO]
Aetna [Weill Cornell Employee Plan]
Affinity [Access (Exchange)]
Cigna [EPO, HMO, Medicare, POS, PPO]
Emblem Select Care
Emblem/HIP [EPO, HMO, Medicaid, Medicare, POS, PPO]
Empire Blue Cross Blue Shield [Blue Priority, Child Health Plus, EPO, HMO, Mediblue (Senior), Pathway (Exchange), PPO]
Empire Blue Cross Blue Shield [Pathway Enhanced]
Empire Blue Cross Blue Shield HealthPlus [MCD]
Oxford Health Plans [Freedom, Liberty, Medicare Advantage]
Oxford Health Plans [Metro/Core/Charter (HMO)]
Rockefeller University - CoreSource
UnitedHealthcare [Community Plan, Compass (Exchange), EPO, HMO, Medicare, POS, PPO]
1987 Mount Sinai School of Medicine
Residency: 1990 Mount Sinai Medical Center
Fellowship: 1994 Memorial Sloan-Kettering Cancer Center